In a new in-depth article Michele Romano, PhD, responsible at BÜHLMANN for the Product Management of the CAST® Assays for Basophil Activation Tests (BAT), writes about the benefits of using BAT assays in drug discovery and preclinical evaluation of kinase inhibitors.
- info@buhlmannlabs.ch
- +41 61 487 12 12
News
Roche Diagnostics Switzerland recently announced the successful collaboration with BÜHLMANN Laboratories AG in bringin the BÜHLMANN fCAL® turbo Calprotectin assay onto their cobas® platform. On the Roche cobas® modular platform the BÜHLMANN fCAL® turbo calprotectin assay can be easily installed and run. In several laboratories on the cobas® c501 modules the assay has been already installed
BÜHLMANN Quantum Blue® fCAL Citation: Abej, E. et al. The Utility of Fecal Calprotectin in the Real-World Clinical Care of Patients with Inflammatory Bowel Disease, Can J Gastroenterol Hepatol. 2016, PMID: 27774443. Highlight from this publication: “Given the noninvasive nature, quick turnaround of FCAL test, and good correlation with endoscopy in colonic inflammatory bowel diseases as we have shown in
BÜHLMANN’s Kinase Inhibition Assay Testing Potency and Efficacy of Inhibitors of PI3K δ, PI3K γ, BTK and SYK Activity Biomarker assays are developed specifically for pharmacokinetic and pharmacodyamic (PK/PD) models during drug discovery and are often used to test efficacy and toxicity. Inhibitors of PI3K, BTK and SYKpathways are a large focus for pharmaceutical companies
Social Links